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Abstract
Chronic fatigue syndrome (CFS) is complex illness of unknown etiology. Among the broad range
of symptoms, many patients report disturbances in the emotional realm, the most frequent of
which is anxiety. Research shows that patients with CFS and other so-called functional somatic
disorders have alterations in the intestinal microbial flora. Emerging studies have suggested that
pathogenic and non-pathogenic gut bacteria might influence mood-related symptoms and even
behavior in animals and humans. In this pilot study, 39 CFS patients were randomized to receive
either 24 billion colony forming units of Lactobacillus casei strain Shirota (LcS) or a placebo daily for
two months. Patients provided stool samples and completed the Beck Depression and Beck
Anxiety Inventories before and after the intervention. We found a significant rise in both
Lactobacillus and Bifidobacteria in those taking the LcS, and there was also a significant decrease in
anxiety symptoms among those taking the probiotic vs controls (p = 0.01). These results lend
further support to the presence of a gut-brain interface, one that may be mediated by microbes
that reside or pass through the intestinal tract.
Background
Chronic Fatigue Syndrome (CFS) is a medically unex-
plained illness, characterized by persistent and relapsing
fatigue [1,2]. This severe pathological fatigue is worsened
by periods of physical and mental exertion. Along with
the ongoing fatigue, it has also been noted that 97% of
CFS patients report neuropsychological disturbances. This
can manifest as cognitive dysfunction, sleep disturbances,
headaches, and a variety of symptoms in the emotional
realm. Of these emotion-related symptoms, anxiety and
depression are the most prevalent, with approximately
half or patients meeting the criteria for an anxiety disorder
or major depressive disorder. Over 40% of patients report
symptoms that are often part of anxiety and depressive
disorders, including dizziness, lightheadedness, heart pal-
pitations, sleep disturbances, appetite changes and short-
ness of breath [3].
Published: 19 March 2009
Gut Pathogens 2009, 1:6 doi:10.1186/1757-4749-1-6
Received: 3 October 2008
Accepted: 19 March 2009
This article is available from: http://www.gutpathogens.com/content/1/1/6
© 2009 Rao et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Gut Pathogens 2009, 1:6 http://www.gutpathogens.com/content/1/1/6
Page 2 of 6
(page number not for citation purposes)
Many CFS patients also complain of gastrointestinal (GI)
disturbances. Indeed, patients with CFS are more likely to
report a previous diagnosis of irritable bowel syndrome
(IBS), meet diagnostic criteria for IBS and experience IBS
related symptoms [4]. While CFS is neither a gastrointes-
tinal nor psychiatric disorder per se, over 50 percent of
patients with CFS meet the diagnostic criteria of IBS, and
anxiety itself is often a hallmark symptom in those with
IBS [5]. Although the mechanisms behind this frequent
overlap with IBS are far from understood, some investiga-
tors have documented that there are marked alterations in
the intestinal microflora of CFS patients, with lower levels
of Bifidobacteria and higher levels of aerobic bacteria [6].
Recently it was discovered that gut pathogens in the GI
tract can communicate with the central nervous system
and influence behavior associated with emotion, anxiety
in particular, even at extremely low levels and in the
absence of an immune response [7,8]. Researchers have
also shown that the administration of certain bacteria
found in soil may support resilience and positively alter
stress-related emotional behavior in animals under exper-
imental stress [9]. In addition, so-called probiotics, or live
microorganisms which confer a health benefit on the
host, have the potential to influence mood-regulating sys-
temic inflammatory cytokines, decrease oxidative stress
and improve nutritional status when orally consumed [6].
This background led some investigators to hypothesize a
possible adjunctive therapeutic role of probiotic bacteria
in mood-related psychiatric symptoms [10]. Some hints at
the utility of probiotics for mood regulation come from a
recent human trial involving the administration of Lacto-
bacillus casei strain Shirota (LcS) or placebo to 132 other-
wise healthy adults. In an intriguing finding, the
investigators discovered that those with the lowest scores
in the depressed/elated dimension at baseline had signif-
icant improvement in mood scores after taking the probi-
otic compared to the placebo group. The probiotic
bacteria and placebo were unable to make a difference in
those with the highest baseline mood scores [11]. In addi-
tion, ongoing experimental studies in this area have
recently shown that in the animal model of depression,
the oral administration of a probiotic can increase plasma
tryptophan levels, decrease serotonin metabolite concen-
trations in the frontal cortext and dopamine metabolite
concentrations in the amygdaloid cortex [12]. With this
background, the current investigation was initiated to
determine if orally administered probiotics could make a
difference in symptoms of depression and anxiety in adult
patients with chronic fatigue syndrome.
Brief Report
Candidates for inclusion were screened from a pool of
CFS patients in a tertiary setting. Those adult patients aged
18–65 meeting the formal diagnostic criteria for CFS,
according to published guidelines, [13] were further
screened for inclusion based on suitability to complete a
two month trial. Excluded were those patients with unsta-
ble physical illness and those with a severity of CFS such
that they were largely bedridden. Also excluded were
patients meeting criteria for psychiatric disorders other
than depression and/or anxiety. The study was approved
by the institutional review board of the University of
Toronto. Patients meeting inclusion criteria provided
written, informed consent at the screening visit after the
procedures had been fully explained.
CFS patients who met all inclusion/exclusion criteria were
evaluated using the Beck Depression Inventory (BDI) and
the Beck Anxiety Inventory (BAI). Patients also provided
stool samples, taken over 3 days, at the evaluation phase.
Kits were provided to the patients according to guidelines
of appropriate collection as per the University of Toronto,
School of Medicine, Department of Nutritional Sciences.
Samples were sent to the Fecal Laboratory of the Univer-
sity of Toronto, Department of Nutrition for evaluation.
Using culture technique, the stool samples were assessed
for total aerobe, anaerobe, Lactobacillus spp, and Bifidobac-
teria spp counts.
After collection of the data and samples at the initial eval-
uation phase, 39 CFS patients were randomized to begin
an intervention phase, an eight-week period where each
patient consumed either a specific lactic acid probiotic
bacteria or placebo by mouth. After each main meal, or
three times daily, patients consumed the contents of an
unmarked sachet containing 8 billion colony forming
units (cfu) of Lactobacillus casei strain Shirota (LcS) or a
placebo with identical taste and appearance. Each CFS
patient in the active intervention group consumed a total
of 24 billion cfu of LcS probiotic per day. Follow-up eval-
uation phase: After 8 weeks of intervention, LcS or pla-
cebo, subjects were re-evaluated by completion of the BDI
and BAI, and a second stool analysis was conducted using
the same collection and culture methods.
Thirty five CFS patients, 27 females and 8 males, com-
pleted the 8-week investigation. Four patients, two from
the LcS probiotic group and two from the placebo group,
withdrew from the study for reasons unrelated to the
intervention. The LcS probiotic powder was well tolerated
and there were no significant adverse events reported in
the probiotic or placebo groups. Compared to the placebo
control group, the treatment group showed moderate
increases in fecal total aerobes and anaerobes and signifi-
cant increases in fecal total Bifidobacteria and Lactobacillus
(Figure 1). Among the Placebo group only 37.5% of sub-
jects showed an increase in Bifidobacteria and 43.8% in
Lactobacillus compared to 73.7% and 73.7% in the treat-Gut Pathogens 2009, 1:6 http://www.gutpathogens.com/content/1/1/6
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ment group respectively (Table 1). The number of subjects
showing changes in fecal Bifidobacteria and Lactobacillus is
also presented in Table 2. An increase in the number of
fecal  Lactobacillus  observed in this study was to be
expected since the probiotic sachets contained high levels
of a specific strain of this bacteria. The positive results
observed with respect to Bifidobacteria are very encourag-
ing since Bifidobacteria levels have been reported to be low
in CFS, and they are generally associated with a healthy
colonic environment. [14]. It can therefore be concluded
that ingestion of the probiotic capsules contributed
towards the predominance of bacteria that are associated
with a healthy gastrointestinal system.
When evaluating the BDI and BAI for changes over the
course of the 8-week study, we found a statistical differ-
ence between the anxiety scores in those taking LcS or the
placebo. Overall there was a significant improvement in
anxiety among those taking the active LcS compared to the
placebo (Table 3). The differences as assessed by the BDI
did not reach statistical significance among those taking
the active LcS.
Discussion
The idea that implanting the intestines with Lactobacillus
strains may improve quality of life and mental health is
not a new one. Dr. George Porter Phillips first reported in
1910 that although Lactobacillus tablets and powder were
ineffective, a gelatin-whey formula with live lactic acid
bacteria improved depressive symptoms in adults with
melancholia [15]. In a series of case reports, separate
researchers concluded in 1923 that 'the administration of
acidophilus milk is recommended in the treatment of psy-
choses as a means to physical betterment' [16]. In this
pilot study we found that the oral administration of Lacto-
bacillus casei strain Shirota (LcS, Yakult Honsha, Tokyo,
Japan) caused a significant rise in fecal Bifidobacteria spp.
and  Lactobacillus spp. The rise in Lactobacilli  was an
expected finding, although the concomitant rise in Bifido-
bacteria suggests that there may be far reaching effects of
oral probiotics on other microbial residents of the gas-
trointestinal tract. This finding supports previous research
showing that the oral administration of Lactobacillus
plantarum 299 V caused a significant rise in fecal Bifidobac-
teria levels [17]. In this case the elevation of Bifidobacteria
levels should be considered a positive finding, particularly
when considering that Bifidobacteria levels may be low in
CFS. Also of relevance is a recent experimental study
which has shown that a specific strain of Bifidobacteria can
boost plasma tryptophan levels and alter serotonin and
dopamine turnover in areas of the brain associated with
depression and anxiety [12]. We also found a significant
reduction in anxiety scores among those CFS patients con-
suming the LcS bacteria. The group differences in anxiety
are noteworthy since anxiety is a frequent mental health
symptom reported by CFS patients.
In recent years the interface between neuropsychiatry and
gastroenterology has converged into a new discipline
referred to as enteric neuroscience. Emerging studies have
shown that intestinal bacteria may directly communicate
with the central nervous system by way of the vagal sen-
sory nerve fibers and the peripheral immune system.
Indeed, experimental studies have shown that even
minute doses of microbes within the gastrointestinal tract,
levels that do not trigger an immune response, are capable
of influencing neurotransmission in the paraventricular
hypothalamus, the central nucleus of the amygdala, and
the bed nucleus of the stria terminalis [8]. All three of
these regions are involved in the processing of emotions
related to anxiety and mood. It is also true that quantita-
Difference in fecal bacteria between 0 ands 8 weeks in pla- cebo and treatment groups Figure 1
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Table 1: Total Fecal Aerobes, Anaerobes, Bifidobacteria and Lactobacillus in Placebo and Treatment Groups
Total Aerobes Total Anaerobes Bifidobacteria Lactobacillus
0 Wk 8 Wk Dif 0 Wk 8 Wk Dif 0 Wk 8 Wk Dif 0 Wk 8 Wk Dif
Placebo 7.98 7.82 -0.16 9.46 9.49 0.03 6.96 6.60 -0.36 5.81 5.96 0.15
Treatment 7.52 7.95 0.43 9.32 9.58 0.26 6.44 7.10 0.66 6.93 8.05 1.12
Values expressed as mean CFU per gram fresh fecal sampleGut Pathogens 2009, 1:6 http://www.gutpathogens.com/content/1/1/6
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tive alterations in the make-up of gastrointestinal
microbes are a consequence of states of stress and fear,
and alterations in the gut microflora have recently been
associated with impaired glucose control and obesity
[18,19].
More hints of a connection between intestinal microflora
and brain function come from studies in the autistic spec-
trum. Research has shown marked alterations of the gas-
trointestinal microflora in autism, with specific elevations
in various Clostridium spp. [20]. Some researchers specu-
late that low-grade chronic intestinal inflammation
induced by elevations in bacteria such as potentially path-
ogenic Clostridium spp may be directly influencing brain
centers. Experimental studies show that indeed chronic
gut inflammation leads to activation of areas of the brain
associated with mental health and behavioral disorders,
including the hypothalamus, amygdala and cortical cent-
ers [21]. While we did not look specifically at Clostridium
spp. in this pilot investigation, it has been noted that
Lactobacillus  can competitively displace Clostridium  and
other potentially pathogenic gut bacteria [22]. Propionic
acid is a short chain fatty acid produced primarily by
Clostridium and Bacteroides spp.; emerging research sug-
gests that this acid may be involved in anxiety. Elevated
production of propionic acid in the gut has been shown
to increase behaviors associated with anxiety and aggres-
sion in animals [23]. It has also been shown recently that
when propionic acid gains access to the brain it can impair
the social behavior of animals. Changes to the animal
behavior include decreased playful behavior, increasing
social isolation, and an increase in repetitive behaviors
that may indicate anxiety [24]. While human data is lack-
ing, a study in animals did show that the LcS as used in
our study can lower cecal propionate levels [25].
Some researchers have stated that the so-called 'hygiene
hypothesis' extends into the realm of mental health disor-
ders as well. The hygiene hypothesis is the proposition
that the documented rise in chronic inflammatory disor-
ders (allergies, autoimmunity, and inflammatory bowel
disease) within developed countries is driven by a chang-
ing microbial environment, an absence of beneficial bac-
teria that has in turn altered the immuno-regulatory
circuits which normally keep inflammatory responses in
check [26]. Many mental health conditions, and so-called
functional somatic disorders such as CFS, have been well-
documented to have elevations in inflammatory
cytokines, and these inflammatory cytokines at even low
levels can produce symptoms of anxiety and depression in
otherwise healthy adults [26]. Therefore, since orally
administered probiotics can decrease inflammatory
cytokines in humans, it has been postulated that bacteria
may be used to positively influence mood in patient pop-
ulations where both emotional symptoms and inflamma-
tory immune chemicals are elevated [10]. It is becoming
increasingly clear that anxiety and stress itself may lower
levels of fecal lactic acid bacteria, and this, in turn, may
compromise various aspects of health [27].
Overall the results suggest that specific strains of probiotic
bacteria may have a role to play in mediating some of the
Table 2: Number of Subjects Showing Changes in Fecal Bifidobacteria and Lactobacillus
BIFIDOBACTERIA LACTOBACILLUS
Total No change Increase Decrease Total No change Increase Decrease
No % No % No % No % No % No %
Placebo 16 - - 6 37.5 10 62.5 16 - - 7 43.8 9 56.2
Treatment 19 - - 14 73.7 5 26.3 19 1 5.3 14 73.7 4 21.0
Table 3: Repeated measures analysis of variance for the BDI and BAI after treatment with placebo or probiotics
BDI BAI
df F Sig df F sig
Baseline Placebo vs. Probiotic 1 1.773 .204 1 .087 .772
Probiotic Treatment Pre vs. Post 1 1.197 .292 1 8.415* .011
X Interaction 1 .452 .513 1 .125 .729
*p < 0.05Gut Pathogens 2009, 1:6 http://www.gutpathogens.com/content/1/1/6
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emotional symptoms of CFS and other related conditions.
However, it is important to note that this is a small pilot
study and broad conclusions cannot be drawn at this
time. Since we did not evaluate bowel function during the
study, it is entirely possible that the decreased anxiety was
a consequence of improved bowel function. In an unex-
plained medical condition such as CFS, where over 70%
of patients meet the criteria for IBS, it is possible that reg-
ulation of bowel movements made a difference in mental
state. Indeed LcS has been shown to regulate bowel func-
tion and decrease constipation in a controlled trial [28]. It
is also true that LcS has been shown to reduce small intes-
tinal bacterial overgrowth and the subjective reporting of
the passage of gas in patients with IBS [29]. This is of sig-
nificance because SIBO and intestinal permeability often
overlap, and patients with chronic fatigue syndrome are
known to have both increased intestinal permeability and
SIBO. Indeed, correction of SIBO and intestinal permea-
bility has been shown to improve symptoms in CFS and
depressive disorders [30,31]. Therefore, it is entirely pos-
sible that our results are an artifact of improved gut struc-
ture and function via the LcS restoration of a healthy
intestinal biofilm. However, a recent study using the same
LcS strain in healthy adults suggests that there may be a
more direct microbial influence on emotional state. In
healthy adults who were reported to be more depressed/
less elated in daily functioning at baseline, there was sig-
nificant improvement in mood scores after taking the pro-
biotic. In that controlled trial the improvements in mood
were not related to changes in bowel function [11].
This preliminary research raises many questions regarding
possible mechanisms whereby probiotics might influence
anxiety and depression. The results of the present study
should be viewed simply as a stimulus for further
research. Follow-up studies with probiotics should further
examine specific gut microbes, intestinal structure and
function as well as physiological markers associated with
anxiety and depression. These may include inflammatory
cytokines and other immune chemicals, blood tryp-
tophan levels and urinary metabolites of neurotransmit-
ters.
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